Everything tagged "insider buying" across the TickerSpark archives.
Battalion Oil's directors just bought 84,400 shares as net debt fell sharply and refinancing pushed maturities to 2029. BATL remains speculative, but the cleanup now looks like an equity thesis rather than a pure distress trade.
ACDC's $5.74 million insider-buying signal gives the Q2 operating rebound more weight than the stock's debt headline. The balance sheet demands a small position, but the improving business trend makes this contrarian setup bullish.
Energy Transfer's $21.51 million insider-buying wave arrives alongside a 32% jump in distributable cash flow. The 6.4% yield, 19-quarter distribution streak, and raised 2026 outlook make ET a compelling bullish income setup.
A $1.62 million purchase by CEO Richard Young gives i-80 Gold's Nevada buildout a level of insider conviction the market cannot dismiss. The bullish case rests on Granite Creek's ramp, Archimedes' Q4 first-gold target and Lone Tree construction, not on today's weak earnings.
Albertsons' 2026 guidance cut was severe, but the market's 30% YTD punishment now collides with $2.41 million of post-reset insider buying. The setup is contrarian: management is signaling value while ACI Edge and the next earnings report test whether the reset is survivable.
OTLK's $5.81 million insider buying is a real vote of confidence, but the company is still funding an approved product with fresh equity. A $55 million stock-and-warrant offering, a 600 million share authorization and ongoing losses keep dilution ahead of durable commercial proof.
CDNL's insider buying is landing alongside 64% organic Q1 growth, a raised 2026 revenue outlook, and record backlog. The stock has cooled, but that reset makes management's conviction more meaningful—not less.
Five Amrize officers bought $839,000 of AMRZ shares just as analysts turned more negative on margins. The damage is real, but pricing actions, Building Materials growth and a stock near its 52-week low make the selloff look excessive.
Attovia's insider signal is bullish, but the cleanly supported figure is $10.29 million rather than the touted $20.57 million. The smaller number still matters because it arrived alongside a roughly $289 million IPO and a lead asset already tested in humans.
Braveheart Bio has a credible bull case as insider-aligned capital backs a lead program with positive Phase 2 data and a late-stage path. The single-asset risk is real, but the size of recent buying makes today’s IPO pullback look more like volatility than a thesis break.
Three insiders bought $9.29 million of BSX shares in roughly two weeks, including a roughly $9 million purchase by CEO Michael Mahoney. That confidence signal lands alongside 19.9% revenue growth, 55.6% EPS growth and a valuation that already reflects a reset.
NMM’s bull case rests on $4.1 billion of contracted revenue, 99.5% fleet utilization and a 6.8x trailing P/E—not a vague shipping-cycle promise. The reported $846.87 million of insider buying adds a powerful signal, though the freshest filings do not fully verify an extraordinary open-market purchase.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime